



Photo available on request

## **Hybrigenics appoints Dr Bernhard Ehmer to its Board of Directors**

**Dr Ehmer, CEO of BioPheresis Technologies, brings 20 years of clinical R&D and business management experience from the pharma industry**

**Paris, August 1, 2006** - Hybrigenics, the protein pathway-based cancer drug discovery and development company, announces today the appointment of Bernhard R M Ehmer, MD, to its supervisory board as a non-executive independent Director.

*"We are delighted to welcome Dr Bernhard Ehmer to our Board of Directors, as he brings a wealth of international experience in clinical development and pharmaceutical marketing in oncology,"* said Rémi Delansorne, Hybrigenics' CEO. *"Bernhard's know-how in bringing anticancer molecules to market will be of tremendous help for Hybrigenics' R&D activities."*

Dr Bernhard Ehmer, 51, is currently CEO of BioPheresis Technologies Inc, a US company focused on the development and commercialization of a patent protected system (OncoSorb(R)) for the immunological treatment of cancer patients, with operational headquarters based in Heidelberg, Germany. At Merck KGaA, Dr Ehmer was successively Head of Clinical R&D Operations (1998-2000), Vice-President for the Business Area Oncology (2000-2005) and for Corporate Strategic Planning and Alliance Management (2005). His leadership played a key role in the development, registration and launch by Merck KGaA of cetuximab (Erbix(R)), a chimeric monoclonal antibody targeting the EGF receptor from Imclone, for cancer indications outside North America. He also mastered a cooperation agreement with Takeda on matuzumab, a humanized monoclonal antibody against EGFR, developed by Merck KGaA.

Before joining Merck KGaA, Dr Ehmer spent 12 years with Boehringer Mannheim GmbH in various clinical R&D and management positions in Germany, Italy and Singapore. Among his major achievements was the extension of the therapeutic indications of recombinant erythropoietin to the supportive treatment of cancer.

Dr Ehmer was resident in Internal Medicine at a teaching hospital of the University of Heidelberg from 1983 to 1986, after having graduated from the universities of Munich and Heidelberg (1976-1982). He is the author or co-author of about 60 scientific articles and co-editor of a book on the use of recombinant erythropoietin in cancer (1996).

**About Hybrigenics:** <http://www.hybrigenics.com>

Hybrigenics is a biotechnology company dedicated to the discovery of molecules active against targets validated using the company's proprietary proteomics and bioinformatics technologies. The company is carrying out its own research programs by screening chemical libraries of small organic molecules against validated targets in oncology. In addition, Hybrigenics is actively developing inecalcitol, a vitamin D analogue, for cancer indications.

Hybrigenics also offers research services through access to its Yeast Two-Hybrid (Y2H) Screening platform and bioinformatics-based analysis of protein-protein interactions. Its fee-for-service activities have received ISO 9001:2000 certification. Its customers are public and private laboratories involved in the identification and validation of targets in all biological or therapeutic areas.

---

Press and analyst contacts

**Hybrigenics**

Patricia Blondel, communications

[pblondel@hybrigenics.com](mailto:pblondel@hybrigenics.com)

Tel: 33 1 58 10 38 11

**Andrew Lloyd & Associates**

Gilles Petitot – Marie-Laure Melchior

Tel : 33 1 56 54 07 00

[gilles@ala.com](mailto:gilles@ala.com), [marielaure@ala.com](mailto:marielaure@ala.com)

---